Non-mutagenic impurities

Non-mutagenic impurities

Supporting the assessment and control of your non-mutagenic impurities and contaminants

Assessment and control of non-mutagenic impurities and contaminants

If an impurity is known to be non-mutagenic or non-carcinogenic, impurity levels in the active pharmaceutical ingredient (API) and drug product, still need to be assessed and controlled. Additionally, the potential for cross-contamination in shared API manufacturing facilities must be evaluated based on the risk posed by identified cross contaminants. Regulatory guidelines require careful evaluation of impurity thresholds to demonstrate that exposure is within acceptable limits and will be safe for human exposure.
First name
Last name
Organisation
Business email address
How can we help?
Where did you hear about Consult Lhasa?
Our privacy policy explains how we use your personal information.

Why choose Consult Lhasa?

Consult Lhasa provide expert risk assessments for non-mutagenic impurities and cross contaminants, built on Lhasa Limited science, that can be trusted by industry and regulatory authorities.

If you need assistance with your non-mutagenic impurity risk assessment, Consult Lhasa.

How can our experts help you to assess
non-mutagenic impurities?



Do you need help establishing safe limits for your non-genotoxic impurities (NGIs)?
When a non-genotoxic impurity (NGI) is present above the qualification threshold, an impurity qualification becomes necessary. We can provide a weight of evidence assessment to determine a safe limit for your NGI.



Does your process involve a residual solvent not included in ICH Q3C?
If a solvent is not included within the ICH Q3C guidelines, an independent calculation is required to determine an acceptable intake. If relevant and robust data exists, we can perform a permitted daily exposure (PDE) risk assessment to establish an acceptable limit for your residual solvent.


What if there is insufficient data for your solvent, not included in ICH Q3C?
In cases where high-quality data for your residual solvent is unavailable, the correct analogue – or class of analogues – needs to be identified. Where possible, we will provide appropriate read-across analogues and utilise the anologue/s to establish an acceptable intake (AI) for your residual solvent.



Do you need help evaluating the level of elemental impurities in your final drug product?
Elemental impurities (EIs) can originate from several sources and need to be controlled to a safe limit. It is important to evaluate each source to understand its contribution to overall EI levels in the final drug product. We can help you to assess the risk of EIs in your final drug product, relative to the permitted daily exposure (PDE), in line with the ICH Q3D guidance. If necessary, based on the risk assessment outcome, we can propose a control strategy.


 

Do you need support defining health based exposure limits?

When multiple medicinal products are manufactured in a shared facility, the risk of cross-contamination should be evaluated. We can provide a structured scientific evaluation of pharmacological and toxicological data to define a health based exposure limit for your product, considering the other products manufactured within the facility. The outcome will be a threshold value e.g. permitted daily exposure (PDE) or threshold of toxicological concern (TTC) .

We provide regulatory support

ICH Q3A
Discover more

ICH Q3A

For qualification of new drug substances produced by chemical synthesis.
Discover more

ICH Q3B

For qualification of impurities in new drug substances produced by chemical syntheses.
Discover more

ICH Q3C

For classifying solvents into one of three classifications, and associating safe limits.
Discover more

ICH Q3D

For assessing and controlling elemental impurities in the drug product, using a risk-based control strategy.

Get in touch

If you are interested in discovering how Consult Lhasa could improve your non-mutagenic impurities risk assessments, get in touch.